Cericlamine

Cericlamine

SCHEMBL114233

CN(C)C(C)(CO)Cc1ccc(Cl)c(Cl)c1

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.45
SIGMAR1 Q99720 5/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
PYCR1 P32322 1/20 0.41
IDO1 P14902 2/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
PNMT P11086 2/20 0.39
TSHR P16473 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
VNN1 O95497 1/20 0.38
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cericlamine SCHEMBL4747551 1.00 FDPS (0.45) FDPSSIGMAR1MEN1ALDH1A1TP53
Cericlamine SCHEMBL29359640 1.00 FDPS (0.45) FDPSSIGMAR1MEN1ALDH1A1TP53
Cericlamine SCHEMBL29486910 0.98 FDPS (0.44) FDPSSIGMAR1MEN1ALDH1A1TP53
Cericlamine SCHEMBL140391 0.98 FDPS (0.44) FDPSSIGMAR1MEN1ALDH1A1TP53
SCHEMBL10771931 0.86 SIGMAR1 (0.42) FDPSSIGMAR1MEN1ALDH1A1TP53
SCHEMBL10771519 0.85 FDPS (0.44) FDPSSIGMAR1MEN1ALDH1A1TP53
SCHEMBL9130196 0.81 FDPS (0.38) FDPSSIGMAR1MEN1ALDH1A1TP53
SCHEMBL9130190 0.81 FDPS (0.38) FDPSSIGMAR1MEN1ALDH1A1TP53
Hydrochloric Acid SCHEMBL9422892 0.80 FDPS (0.38) FDPSSIGMAR1MEN1ALDH1A1TP53
SCHEMBL9776021 0.76 PNMT (0.42) FDPSSIGMAR1MEN1ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2723 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12514883-B2 Compositions and methods for modulating lipid and steroid metabolism THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-01-06 US claimed
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 WO claimed
EP-4536231-A1 TREATMENT OF ANTIDEPRESSANT RESISTANT SUBJECTS Actinogen Medical Limited (AU) 2025-04-16 EP claimed
WO-2023235937-A1 TREATMENT OF ANTIDEPRESSANT RESISTANT SUBJECTS Actinogen Medical Limited (AU) 2023-12-14 WO claimed
US-20230381168-A1 ADJUNCTIVE THERAPY FOR DEPRESSION ANEUROTECH BV (BE) 2023-11-30 US claimed
US-20220347127-A1 USE OF ANTIDEPRESSANT AGENTS FOR PREVENTING AND TREATING THE COVID-19 DISEASE ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) 2022-11-03 US claimed
US-20220265641-A1 SEROTONERGIC AGENT AND 5-HT1A-RECEPTOR ANTAGONIST ATLAS PHARMACEUTICALS BV (BE) 2022-08-25 US claimed
WO-2022159506-A1 DEUTERATED CANNABIDIOL COMPOUNDS MERIT THERAPEUTICS, INC. (US) 2022-07-28 WO claimed
WO-2022159507-A1 COMBINATION OF CANNABINOIDS WITH ADDITIONAL THERAPEUTIC AGENTS FOR TREATING DISEASES OR DISORDERS MERIT THERAPEUTICS, INC. (US) 2022-07-28 WO claimed
EP-1931320-B1 MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME FLAMEL IRELAND LTD (IE) 2022-06-15 EP claimed
EP-0977558-A2 USE OF 5HT4 RECEPTOR ANTAGONISTS FOR OVERCOMING GASTROINTESTINAL EFFECTS OF SEROTONIN REUPTAKE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2000-02-09 EP claimed
EP-0973724-A1 NOVEL PROCESS FOR THE PREPARATION OF (+/-)3- (3,4-DICHLOROPHENYL)-2- DIMETHYLAMINO-2-METHYLPROPAN-1-OL OR CERICLAMINE (INN) PARKE-DAVIS (FR) 2000-01-26 EP claimed
US-5990159-A Use of 5HT4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 1999-11-23 US claimed
US-5977099-A Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors AKZO NOBEL, N.V. (NL) 1999-11-02 US claimed
WO-1998045248-A1 NOVEL PROCESS FOR THE PREPARATION OF (+/-)3- (3,4-DICHLOROPHENYL)-2- DIMETHYLAMINO-2-METHYLPROPAN-1-OL OR CERICLAMINE (INN) JOUVEINAL (FR) 1998-10-15 WO claimed
CN-1173330-A Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitiors AKZO NOBEL NV (NL) 1998-02-18 CN claimed
EP-0813873-A1 Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors Akzo Nobel N.V. (NL) 1997-12-29 EP claimed
WO-1997029739-A2 USE OF 5HT4 RECEPTOR ANTAGONISTS FOR OVERCOMING GASTROINTESTINAL EFFECTS OF SEROTONIN REUPTAKE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 1997-08-21 WO claimed
WO-1992000103-A1 PHARMACEUTICAL PREPARATIONS BEECHAM GROUP PLC (GB) 1992-01-09 WO claimed
US-4994617-A Analgesics JOUVEINAL S.A. (FR) 1991-02-19 US claimed